This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Zoetis Inc. came into existence following Pfizer’s decision to spin off its animal health business. he company is a leader in the discovery, development, manufacture and commercialization of animal health medicines, vaccines and diagnostic products with a focus on both livestock and companion animals. Zoetis has a diversified business, which caters to eight core species — cattle, swine, poultry, fish and sheep (collectively, livestock) and dogs, cats and horses (collectively, companion animals).
Top Stock Reports for Cisco, Enterprise Products Partners & Prudential
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Cisco (CSCO), Enterprise Products Partners (EPD), and Prudential (PRU).
Zoetis (ZTS) Beats on Q2 Earnings & Sales, Ups 2017 View
by Zacks Equity Research
Zoetis (ZTS) reported impressive second-quarter results beating on both counts. The new launches and expansion of market for major products helped revenue growth.
Zoetis (ZTS) Q2 Earnings In-line, Sales Beat; 2017 View Up
by Zacks Equity Research
Zoetis (ZTS) reported an in-line earnings per share while revenues beat estimates in the second quarter 2017.
Should You Buy Zoetis (ZTS) Ahead of Earnings?
by Zacks Equity Research
Zoetis (ZTS) is seeing encouraging earnings estimate revision activity as of late and carries a favorable rank, positioning the company for a likely beat this season.
Is Zoetis (ZTS) Poised for a Beat This Earnings Season?
by Zacks Equity Research
Zoetis, Inc. (ZTS) is expected to focus on performance of companion animal business during its second-quarter results.
Adamas Provides Positive Long-term Data on Parkinson's Drug
by Zacks Equity Research
Adamas Pharmaceuticals, Inc. (ADMS) presented expanded analysis from an ongoing open label phase III study EASE LID 2 on its lead candidate, ADS-5102 extended-release capsules.
Zoetis (ZTS) Up 6.4% Since Earnings Report: Can It Continue?
by Zacks Equity Research
Zoetis (ZTS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Roche (RHHBY) Presents Positive Data on IPF Drug Esbriet
by Zacks Equity Research
Roche Holding AG (RHHBY) announced new retrospective data analyses for idiopathic pulmonary fibrosis (IPF) drug, Esbriet.
Inovio (INO) Stock Rises on Encouraging HIV Vaccine Data
by Zacks Equity Research
Inovio Pharmaceuticals Inc. (INO) shares have rallied 12% since the company announced that its HIV vaccine evoked almost 100% immune response rates in a clinical study
Horizon (HZNP) Sells European Rights for Procysbi & Quinsair
by Zacks Equity Research
Horizon Pharma plc (HZNP) signed an agreement with Chiesi Farmaceutici S.p.A. to sell European rights for Procysbi and Quinsair.
Roche's Arthritis Drug Gets FDA Nod for Label Expansion
by Zacks Equity Research
Roche Holdings AG (RHHBY) announced that the FDA has approved Actemra subcutaneous injection for the treatment of giant cell arteritis (GCA).
Celgene (CELG) Multiple Sclerosis Drug Meets Primary Endpoint
by Zacks Equity Research
Celgene Corporation (CELG) announced positive results from the phase III trial, RADIANCE that evaluated the efficacy and safety of experimental candidate ozanimod.
Adamas Epilepsy Drug Shows Positive Result in Phase Ia Study
by Zacks Equity Research
Adamas Pharmaceuticals, Inc. (ADMS) announced positive data from thephase Ia study evaluating ADS-4101 (lacosamide) for the treatment of partial onset seizures in epilepsy.
AstraZeneca Sells Marketing Rights to Seloken in Europe
by Zacks Equity Research
AstraZeneca plc (AZN) announced that it has signed an agreement with Recordati S.p.A, granting commercial rights to Seloken/Seloken ZOK and associated Logimax fixed-dose combination to the latter in European markets.
Zoetis (ZTS) Tops Earnings & Sales in Q1, Keeps 2017 View
by Madhu Goel
Zoetis reported earnings of 53 cents per share beating the Zacks Consensus Estimate of 48 cents.
What's in Store for Zoetis (ZTS) Stock This Earnings Season?
by Zacks Equity Research
Zoetis Inc. (ZTS) is scheduled to report first-quarter 2017 results on May 4.
Why Is Zoetis (ZTS) Up 3.1% Since the Last Earnings Report?
by Zacks Equity Research
Zoetis (ZTS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Top Research Reports for March 9, 2017
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including IBM (IBM), Celgene (CELG), and Shell (RDS.A).
Zoetis (ZTS) Beats Q4 Earnings Estimates, Lowers Outlook
by Zacks Equity Research
Zoetis Inc. (ZTS) topped earnings estimates in the fourth-quarter of 2016 while revenues came in line. The company also narrowed its outlook for 2017 to account for currency impact.
Zoetis (ZTS) Tops on Earnings in Q4, Updates View
by Ekta Bagri
Zoetis has surpassed earnings estimates in Q4 but revenues came in line. The company also updated its outlook for 2017.
5 Easy Money Momentum Stocks To Buy Now
by David Bartosiak
These 5 stocks are breaking through to new 52-week highs on huge momentum
Top Research Reports for December 29, 2016
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Wells Fargo (WFC), Danaher (DHR) and Colgate-Palmolive (CL).
Top Research Reports for Broadcom, PNC Financial & ConocoPhillips
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Broadcom (AVGO), PNC Financial Services (PNC) and ConocoPhillips (COP).
5 Healthcare Stocks Poised to Trump Q3 Earnings
by Zacks Equity Research
Medical is one of the many sectors that is witnessing earnings and revenue growth this quarter.
Top Research Reports for August 19, 2016
by Sheraz Mian
Today's must-read reports are for Verizon (VZ), Comcast (CMCSA) and Teva (TEVA).